Apparatus and mitochondrial treatment for glaucoma

• US 20030097151A1
• Filed: 10/25/2002
• Published: 05/22/2003
• Est. Priority Date: 10/25/2001
• Status: Abandoned Application

• Current Assignee: Glaukos Corporation
• Original Assignee: Glaukos Corporation
• Inventors: Smedley, Gregory T., Tu, Hosheng
• Application Number:
  US10/281,873
• Publication Number:
  US 20030097151A1
• Time in Patent Office: Days
• US Class Current: 607/2
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61N 1/40 Applying electric fields by inductive or capacitive coupling microwave apparatus A61N5/00; Applying radio-frequency signals
• CPC Class Codes: A61N 5/0601 Apparatus for use inside the body

Abstract

A method is provided for treatment of glaucoma comprising stimulating mitochondria of ophthalmologic cells with energy effective for stimulating the mitochondria, wherein the energy source may be a physical source or biochemical source of monoamine oxidase inhibitors. A unique endoscope-microscope interface is disclosed which advantageously provides a simultaneous view of the microscope field of view and the endoscope field of view to the operator or surgeon.

Claims

1. A method of treating mitochondria in a cell of a glaucoma patient comprising stimulating mitochondria of the cell with an energy source sufficient to increase cellular energy production.

2. The method of claim 1, wherein the energy is selected from the group consisting of ultrasound energy, microwave energy, optical light energy, laser energy, and electromagnetic energy.

3. The method of claim 2, wherein a mode of delivering energy is selected from the group consisting of continuous, intermittent, and programmed.

4. The method of claim 1, wherein the energy is provided by a mitochondrial stimulating agent.

5. The method of claim 4, wherein the mitochondrial stimulating agent is a monoamine oxidase inhibitor.

6. The method of claim 5, wherein the monoamine oxidase inhibitor is a deprenyl compound.

7. The method of claim 4, wherein the mitochondrial stimulating agent is loaded onto or within an ophthalmologic implant.

8. The method of claim 7, wherein the ophthalmologic implant is a trabecular stent that is configured to be implantable in a trabecular meshwork of the patient.

9. The method of claim 7, wherein the ophthalmologic implant is implanted in a posterior chamber of the patient'"'"'s eye.

10. The method of claim 7, wherein the ophthalmologic implant is implanted in an anterior chamber of the patient'"'"'s eye.